Author | ART | Dose | Adjuvant CT | Follow-up (m) | G3 acute toxicity | Late toxicity |
---|---|---|---|---|---|---|
Balalchandran et al. [14] | NR | NR | Yes | NR | NR | NR |
Borghero et al. [15] | EBRT | 45 Gy + (boost: 10 Gy) | Yes | 31 | 3 gastrointestinal, 3 hematological | 2 gastrointestinal ulcers, 1 biliary stenosis |
Cheng et al. [16] | EBRT | 50 Gy (44–56 Gy) | No | 21 | Nausea, vomiting | 3 hepaticojejunostomy stenosis, 2 gastroduodenal bleeding |
Gerhards et al. [17] | EBRT+/−IORT | EBRT: 46 Gy; EBRT+ IORT: 62 Gy | NR | 28.8 | abdominal pain, nausea, fever, diarrhea | Cholangitis, abdominal pain, ileus, high gastrointestinal bleeding, Roux-en-Y stenosis |
Gold et al. [18] | EBRT | 50.4 Gy | Yes | 45 | NR | NR |
Gu et al. [19] | EBRT | 50 Gy + boost: 5–10 Gy | Yes | 20 | No | No |
Heron et al. [20] | EBRT+IORT | 46 Gy | No | 22 | No | No |
Hughes et al. [21] | EBRT | 50.4 Gy (40–54 Gy) | Yes | 41 | NR | NR |
Im et al. [22] | EBRT | 50.4 Gy (41.4–54 Gy) | Yes | 63 | NR | NR |
Itoh et al. [23] | EBRT | 52.3 Gy (37.8–79.8 Gy) | No | 32 | NR | NR |
Kim et al. [24] | EBRT | 50.4 Gy (40–54 Gy) | Yes/No | 24 | No | 2 duodenal ulcer |
Liang et al. [25] | EBRT | 50 Gy (40–64 Gy) | Yes/No | 38.5 | NR | NR |
Lee et al. [26] | NR | NR | Yes | NR | NR | NR |
Lindell et al. [27] | EBRT+/−IORT | EBRT: 40 Gy (IORT: 20 Gy) | Yes/No | NR | NR | NR |
Meng et al. [28] | EBRT | 52 Gy (45–62 Gy) | NR | 30 | No | No |
Pitt et al. [29] | EBRT+IORT | NR | NR | NR | NR | Intestinal obstruction, hepatotoxicity, liver abscess |
Sagawa et al. [30] | EBRT+IORT | EBRT: 37.5 Gy / EBRT+ IORT: 73.8 Gy | NR | 32 | NR | 1 bile duct stricture, 1 venous hemorrhage |
Todoroki et al. [31] | EBRT+/−IORT | EBRT: 40.0 Gy (IORT: 20 Gy) | NR | NR | NR | NR |
Todoroki et al. [32] | EBRT+/−IORT | EBRT: 43.6 Gy (IORT: 21 Gy) | NR | 30 | 1 liver necrosis | NR |
Wang et al. [33] | EBRT | 45 Gy + boost: 5.4 Gy | Yes | 47.3 | NR | NR |
Zlotecki et al. [34] | EBRT | 45 Gy (30–60 Gy) | NR | 18 | No | No |